MedTrace Logo

Placebo-controlled Trial in Subjects at Ultra-high Risk for Psychosis With Omega-3 Fatty Acids in Europe

NCT02597439 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 145

Last updated 2023-02-14

No results posted yet for this study

Summary

The purpose of this study is to determine whether omega-3 fatty acids are effective in the prevention of psychosis in individuals at ultra-high risk for psychosis.

Conditions

  • Ultra High Risk for Psychosis

Interventions

DRUG

Omega-3 fatty acids

OTHER

Placebo

Sponsors & Collaborators

  • Rene Kahn

    lead OTHER

Principal Investigators

  • René Kahn, Prof. Dr. · UMC Utrecht

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
13 Years
Max Age
20 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-09-30
Primary Completion
2023-02-01
Completion
2023-02-01

Countries

  • Austria
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Norway
  • Spain
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02597439 on ClinicalTrials.gov